Wednesday’s Battelle Report was followed by Thursday’s Supreme Court Ruling for no more gene patenting on naturally occurring genes. This was a huge win for scientists, medical personnel, and, especially, for individuals. What does this mean for us? For one things, if we have a mutation that has been found and we want to know if our children have the same mutation, the cost of having targeted sequencing for them has dropped significantly. Hours after the ruling, biotech companies are already coming out with other BRCA 1 & 2 tests that are a fraction of the cost that Myriad Genetics used. This is a huge step forward to allowing more innovation at to take place and offer it to the public at better prices. To read more, go to: National Geographic Supreme Court Gene Patent Ruling
